Third, this cohort has been active since 2009, and contemporary anti-diabetic medications, such as sodium glucose co-transporters 2 inhibitors and glucagon-like peptide-1 receptor agonists, which can reduce mortality risk in patients with type 2 diabetes, were seldom prescribed. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.